1	Impaired	Impaired	B-NP	JJ	O	2	NMOD	0
2	apoptosis	apoptosis	I-NP	NN	O	7	SUB	5	apoptosis
3	of	of	B-PP	IN	O	2	NMOD	-1
4	pulmonary	pulmonary	B-NP	JJ	B-cell_type	6	NMOD	-1
5	endothelial	endothelial	I-NP	JJ	I-cell_type	6	NMOD	-1
6	cells	cell	I-NP	NNS	I-cell_type	3	PMOD	-1
7	is	be	B-VP	VBZ	O	0	ROOT	-1
8	associated	associate	I-VP	VBN	O	7	VC	0
9	with	with	B-PP	IN	O	8	VMOD	-1
10	intimal	intimal	B-NP	JJ	O	11	NMOD	-1
11	proliferation	proliferation	I-NP	NN	O	13	NMOD	4	proliferation
12	and	and	I-NP	CC	O	13	NMOD	-1
13	irreversibility	irreversibility	I-NP	NN	O	9	PMOD	-1
14	of	of	B-PP	IN	O	13	NMOD	-1
15	pulmonary	pulmonary	B-NP	JJ	O	16	NMOD	-1
16	hypertension	hypertension	I-NP	NN	O	14	PMOD	-1
17	in	in	B-PP	IN	O	16	NMOD	-1
18	congenital	congenital	B-NP	JJ	O	20	NMOD	-1
19	heart	heart	I-NP	NN	O	20	NMOD	-1
20	disease	disease	I-NP	NN	O	17	PMOD	-1
21	.	.	O	.	O	7	P	-1

1	OBJECTIVES	OBJECTIVES	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	This	This	B-NP	DT	O	4	NMOD	-1
4	study	study	I-NP	NN	O	5	SUB	-1
5	sought	seek	B-VP	VBD	O	1	NMOD	-1
6	to	to	I-VP	TO	O	7	VMOD	-1
7	assess	assess	I-VP	VB	O	5	VMOD	-1
8	the	the	B-NP	DT	O	12	NMOD	-1
9	cellular	cellular	I-NP	JJ	O	11	AMOD	-1
10	and	and	I-NP	CC	O	11	AMOD	-1
11	histologic	histologic	I-NP	JJ	O	12	NMOD	-1
12	basis	basis	I-NP	NN	O	7	OBJ	-1
13	of	of	B-PP	IN	O	12	NMOD	-1
14	irreversible	irreversible	B-NP	JJ	O	16	NMOD	-1
15	pulmonary	pulmonary	I-NP	JJ	O	16	NMOD	-1
16	hypertension	hypertension	I-NP	NN	O	13	PMOD	-1
17	(	(	O	(	O	19	DEP	-1
18	PHT	PHT	B-NP	NN	O	19	DEP	-1
19	)	)	O	)	O	16	NMOD	-1
20	in	in	B-PP	IN	O	16	NMOD	-1
21	the	the	B-NP	DT	O	23	NMOD	-1
22	clinical	clinical	I-NP	JJ	O	23	NMOD	-1
23	setting	setting	I-NP	NN	O	20	PMOD	-1
24	of	of	B-PP	IN	O	23	NMOD	-1
25	congenital	congenital	B-NP	JJ	O	27	NMOD	-1
26	heart	heart	I-NP	NN	O	27	NMOD	-1
27	disease	disease	I-NP	NN	O	24	PMOD	-1
28	(	(	O	(	O	30	DEP	-1
29	CHD	CHD	B-NP	NN	O	30	DEP	-1
30	)	)	O	)	O	27	NMOD	-1
31	.	.	O	.	O	1	P	-1

1	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Although	Although	B-SBAR	IN	O	14	VMOD	-1
4	many	many	B-NP	JJ	O	5	NMOD	-1
5	children	child	I-NP	NNS	O	8	SUB	-1
6	with	with	B-PP	IN	O	5	NMOD	-1
7	CHD	CHD	B-NP	NN	O	6	PMOD	-1
8	develop	develop	B-VP	VBP	O	3	SBAR	-1
9	pulmonary	pulmonary	B-NP	JJ	O	11	NMOD	-1
10	vascular	vascular	I-NP	JJ	O	11	NMOD	-1
11	disease	disease	I-NP	NN	O	8	OBJ	-1
12	,	,	O	,	O	14	P	-1
13	it	it	B-NP	PRP	O	14	SUB	-1
14	is	be	B-VP	VBZ	O	1	NMOD	-1
15	unclear	unclear	B-ADJP	JJ	O	14	PRD	-1
16	why	why	B-ADVP	WRB	O	14	VMOD	-1
17	this	this	B-NP	DT	O	18	NMOD	-1
18	complication	complication	I-NP	NN	O	19	SUB	-1
19	is	be	B-VP	VBZ	O	16	SBAR	-1
20	reversible	reversible	B-ADJP	JJ	O	19	PRD	-1
21	after	after	B-SBAR	IN	O	19	VMOD	-1
22	complete	complete	B-NP	JJ	O	23	NMOD	-1
23	repair	repair	I-NP	NN	O	21	PMOD	0
24	in	in	B-PP	IN	O	23	NMOD	-1
25	some	some	B-NP	DT	O	26	NMOD	-1
26	cases	case	I-NP	NNS	O	24	PMOD	-1
27	but	but	O	CC	O	23	DEP	-1
28	irreversible	irreversible	B-ADJP	JJ	O	23	NMOD	-1
29	in	in	B-PP	IN	O	28	AMOD	-1
30	others	other	B-NP	NNS	O	29	PMOD	-1
31	.	.	O	.	O	14	P	-1

1	Because	Because	B-SBAR	IN	O	20	VMOD	-1
2	failure	failure	B-NP	NN	O	7	SUB	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	endothelial	endothelial	B-NP	JJ	B-cell_type	6	NMOD	-1
5	cell	cell	I-NP	NN	I-cell_type	6	NMOD	-1
6	apoptosis	apoptosis	I-NP	NN	O	3	PMOD	5	apoptosis
7	might	might	B-VP	MD	O	1	SBAR	-1
8	lead	lead	I-VP	VB	O	7	VC	0
9	to	to	B-PP	TO	O	8	VMOD	-1
10	intimal	intimal	B-NP	JJ	O	11	NMOD	-1
11	proliferation	proliferation	I-NP	NN	O	13	NMOD	4	proliferation
12	and	and	I-NP	CC	O	13	NMOD	-1
13	lack	lack	I-NP	NN	O	9	PMOD	-1
14	of	of	B-PP	IN	O	13	NMOD	-1
15	reversibility	reversibility	B-NP	NN	O	14	PMOD	-1
16	of	of	B-PP	IN	O	15	NMOD	-1
17	PHT	PHT	B-NP	NN	B-protein	16	PMOD	-1
18	,	,	O	,	O	20	P	-1
19	we	we	B-NP	PRP	O	20	SUB	-1
20	investigated	investigate	B-VP	VBD	O	0	ROOT	-1
21	this	this	B-NP	DT	O	25	NMOD	-1
22	and	and	O	CC	O	25	NMOD	-1
23	other	other	B-NP	JJ	O	25	NMOD	-1
24	key	key	I-NP	JJ	O	25	NMOD	-1
25	markers	marker	I-NP	NNS	O	20	OBJ	-1
26	of	of	B-PP	IN	O	25	NMOD	-1
27	vasoactivity	vasoactivity	B-NP	NN	O	29	NMOD	-1
28	and	and	I-NP	CC	O	29	NMOD	-1
29	angiogenesis	angiogenesis	I-NP	NN	O	26	PMOD	3	angiogenesis
30	in	in	B-PP	IN	O	29	NMOD	-1
31	subjects	subject	B-NP	NNS	O	30	PMOD	-1
32	with	with	B-PP	IN	O	31	NMOD	-1
33	PHT	PHT	B-NP	NN	B-protein	35	NMOD	-1
34	and	and	I-NP	CC	O	35	NMOD	-1
35	CHD	CHD	I-NP	NN	O	32	PMOD	-1
36	.	.	O	.	O	20	P	-1

1	METHODS	METHODS	B-NP	NNS	O	36	NMOD	-1
2	:	:	O	:	O	1	P	-1
3	We	We	B-NP	PRP	O	4	SUB	-1
4	assessed	assess	B-VP	VBD	O	36	NMOD	-1
5	antiapoptotic	antiapoptotic	B-NP	JJ	O	7	AMOD	-1
6	and	and	I-NP	CC	O	7	AMOD	-1
7	proapoptotic	proapoptotic	I-NP	JJ	B-protein	8	NMOD	-1
8	markers	marker	I-NP	NNS	I-protein	4	OBJ	-1
9	in	in	B-PP	IN	O	8	NMOD	-1
10	vascular	vascular	B-NP	JJ	O	13	NMOD	-1
11	and	and	I-NP	CC	O	13	NMOD	-1
12	perivascular	perivascular	I-NP	JJ	B-cell_type	13	NMOD	-1
13	cells	cell	I-NP	NNS	I-cell_type	9	PMOD	-1
14	in	in	B-PP	IN	O	13	NMOD	-1
15	lung	lung	B-NP	NN	O	17	NMOD	-1
16	biopsy	biopsy	I-NP	NN	O	17	NMOD	-1
17	samples	sample	I-NP	NNS	O	14	PMOD	-1
18	from	from	B-PP	IN	O	17	NMOD	-1
19	18	18	B-NP	CD	O	20	NMOD	-1
20	patients	patient	I-NP	NNS	O	18	PMOD	-1
21	with	with	B-PP	IN	O	20	NMOD	-1
22	CHD	CHD	B-NP	NN	O	21	PMOD	-1
23	,	,	O	,	O	36	P	-1
24	7	7	B-NP	CD	O	36	NMOD	-1
25	with	with	B-PP	IN	O	24	NMOD	-1
26	reversible	reversible	B-NP	JJ	O	28	NMOD	-1
27	and	and	I-NP	CC	O	28	NMOD	-1
28	11	11	I-NP	CD	O	25	PMOD	-1
29	with	with	B-PP	IN	O	28	NMOD	-1
30	irreversible	irreversible	B-NP	JJ	O	31	NMOD	-1
31	PHT	PHT	I-NP	NN	O	29	PMOD	-1
32	,	,	O	,	O	36	P	-1
33	and	and	O	CC	O	36	NMOD	-1
34	6	6	B-NP	CD	O	36	NMOD	-1
35	control	control	I-NP	NN	O	36	NMOD	0
36	patients	patient	I-NP	NNS	O	0	ROOT	-1
37	.	.	O	.	O	36	P	-1

1	Immunostaining	Immunostaining	B-NP	NN	O	22	SUB	-1
2	for	for	B-PP	IN	O	1	NMOD	-1
3	endothelial	endothelial	B-NP	JJ	B-protein	6	NMOD	-1
4	nitric	nitric	I-NP	JJ	I-protein	6	NMOD	-1
5	oxide	oxide	I-NP	NN	I-protein	6	NMOD	-1
6	synthase	synthase	I-NP	NN	I-protein	14	NMOD	-1
7	,	,	O	,	O	14	P	-1
8	vascular	vascular	B-NP	JJ	B-protein	11	NMOD	-1
9	endothelial	endothelial	I-NP	JJ	I-protein	11	NMOD	-1
10	growth	growth	I-NP	NN	I-protein	11	NMOD	0
11	factor	factor	I-NP	NN	I-protein	14	NMOD	-1
12	,	,	O	,	O	14	P	-1
13	and	and	O	CC	O	14	NMOD	-1
14	CD34	CD34	B-NP	NN	B-protein	2	PMOD	-1
15	(	(	O	(	O	21	DEP	-1
16	markers	marker	B-NP	NNS	O	21	DEP	-1
17	of	of	B-PP	IN	O	16	NMOD	-1
18	vasoactivity	vasoactivity	B-NP	NN	O	20	NMOD	-1
19	and	and	I-NP	CC	O	20	NMOD	-1
20	neoangiogenesis	neoangiogenesis	I-NP	NN	O	17	PMOD	3	neoangiogenesis
21	)	)	O	)	O	14	NMOD	-1
22	was	be	B-VP	VBD	O	0	ROOT	-1
23	also	also	I-VP	RB	O	22	VMOD	-1
24	performed	perform	I-VP	VBN	O	22	VC	-1
25	.	.	O	.	O	22	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	The	The	B-NP	DT	O	6	NMOD	-1
4	antiapoptotic	antiapoptotic	I-NP	JJ	B-protein	6	NMOD	-1
5	protein	protein	I-NP	NN	I-protein	6	NMOD	-1
6	Bcl-2	Bcl-2	I-NP	NN	B-protein	7	SUB	-1
7	was	be	B-VP	VBD	O	1	NMOD	-1
8	highly	highly	I-VP	RB	O	7	VMOD	-1
9	expressed	express	I-VP	VBN	O	7	VC	9	expressed
10	by	by	B-PP	IN	O	9	VMOD	-1
11	pulmonary	pulmonary	B-NP	JJ	B-cell_type	13	NMOD	-1
12	endothelial	endothelial	I-NP	JJ	I-cell_type	13	NMOD	-1
13	cells	cell	I-NP	NNS	I-cell_type	10	PMOD	-1
14	in	in	B-PP	IN	O	13	NMOD	-1
15	all	all	B-NP	DT	O	16	NMOD	-1
16	cases	case	I-NP	NNS	O	14	PMOD	-1
17	of	of	B-PP	IN	O	16	NMOD	-1
18	irreversible	irreversible	B-NP	JJ	O	19	NMOD	-1
19	PHT	PHT	I-NP	NN	O	17	PMOD	-1
20	but	but	B-PP	CC	O	10	PMOD	-1
21	in	in	B-PP	IN	O	10	PMOD	-1
22	no	no	B-NP	DT	O	23	NMOD	-1
23	cases	case	I-NP	NNS	O	21	PMOD	-1
24	of	of	B-PP	IN	O	23	NMOD	-1
25	reversible	reversible	B-NP	JJ	O	26	NMOD	-1
26	PHT	PHT	I-NP	NN	O	24	PMOD	-1
27	,	,	B-PP	,	O	21	P	-1
28	nor	nor	I-PP	CC	O	21	PMOD	-1
29	in	in	B-PP	IN	O	21	PMOD	-1
30	control	control	B-NP	NN	O	31	NMOD	0
31	patients	patient	I-NP	NNS	O	29	PMOD	-1
32	(	(	O	(	O	37	DEP	-1
33	p	p	B-NP	NN	O	37	DEP	-1
34	less	less	B-ADJP	JJR	O	33	NMOD	-1
35	than	than	B-PP	IN	O	34	AMOD	-1
36	0.001	0.001	B-NP	CD	O	35	PMOD	-1
37	)	)	O	)	O	31	NMOD	-1
38	.	.	O	.	O	1	P	-1

1	Intimal	Intimal	B-NP	JJ	O	2	NMOD	-1
2	proliferation	proliferation	I-NP	NN	O	3	SUB	4	proliferation
3	was	be	B-VP	VBD	O	0	ROOT	-1
4	present	present	B-ADJP	JJ	O	3	PRD	0
5	in	in	B-PP	IN	O	4	AMOD	-1
6	10	10	B-NP	CD	O	7	AMOD	-1
7	of	of	B-PP	IN	O	5	PMOD	-1
8	11	11	B-NP	CD	O	7	AMOD	-1
9	irreversible	irreversible	I-NP	JJ	O	11	NMOD	-1
10	PHT	PHT	I-NP	NN	O	11	NMOD	-1
11	cases	case	I-NP	NNS	O	7	PMOD	-1
12	,	,	O	,	O	3	P	-1
13	but	but	O	CC	O	3	VMOD	-1
14	never	never	B-VP	RB	O	3	VMOD	-1
15	observed	observe	I-VP	VBN	O	3	VC	0
16	in	in	B-PP	IN	O	15	VMOD	-1
17	reversible	reversible	B-NP	JJ	O	18	NMOD	-1
18	PHT	PHT	I-NP	NN	O	16	PMOD	-1
19	(	(	O	(	O	24	DEP	-1
20	p	p	B-NP	NN	O	24	DEP	-1
21	less	less	B-ADJP	JJR	O	20	NMOD	-1
22	than	than	B-PP	IN	O	21	AMOD	-1
23	0.001	0.001	B-NP	CD	O	22	PMOD	-1
24	)	)	O	)	O	18	NMOD	-1
25	.	.	O	.	O	3	P	-1

1	Similarly	Similarly	B-ADVP	RB	O	6	VMOD	-1
2	,	,	O	,	O	6	P	-1
3	perivascular	perivascular	B-NP	JJ	B-cell_type	5	NMOD	-1
4	inflammatory	inflammatory	I-NP	JJ	I-cell_type	5	NMOD	-1
5	T-cells	T-cell	I-NP	NNS	I-cell_type	6	SUB	-1
6	expressed	express	B-VP	VBD	O	0	ROOT	0
7	more	more	B-NP	RBR	O	8	AMOD	-1
8	antiapoptotic	antiapoptotic	I-NP	JJ	B-protein	9	NMOD	-1
9	proteins	protein	I-NP	NNS	I-protein	6	OBJ	-1
10	in	in	B-PP	IN	O	6	VMOD	-1
11	irreversible	irreversible	B-NP	JJ	O	12	NMOD	-1
12	PHT	PHT	I-NP	NN	O	10	PMOD	-1
13	(	(	O	(	O	18	DEP	-1
14	p	p	B-NP	NN	O	16	SUB	-1
15	less	less	B-ADJP	JJR	O	16	AMOD	-1
16	than	than	B-PP	IN	O	18	DEP	-1
17	0.01	0.01	B-NP	CD	O	16	AMOD	-1
18	)	)	O	)	O	6	VMOD	-1
19	.	.	O	.	O	6	P	-1

1	Irreversible	Irreversible	B-NP	JJ	O	3	NMOD	-1
2	PHT	PHT	I-NP	NN	O	3	NMOD	-1
3	cases	case	I-NP	NNS	O	4	SUB	-1
4	were	be	B-VP	VBD	O	0	ROOT	-1
5	also	also	B-ADVP	RB	O	4	VMOD	-1
6	more	more	B-ADJP	RBR	O	7	AMOD	-1
7	likely	likely	I-ADJP	JJ	O	4	PRD	-1
8	to	to	B-VP	TO	O	9	VMOD	-1
9	show	show	I-VP	VB	O	7	AMOD	-1
10	compensatory	compensatory	B-NP	JJ	O	11	NMOD	-1
11	upregulation	upregulation	I-NP	NN	O	21	NMOD	17	upregulation
12	of	of	B-PP	IN	O	11	NMOD	-1
13	vascular	vascular	B-NP	JJ	B-protein	16	NMOD	-1
14	endothelial	endothelial	I-NP	JJ	I-protein	16	NMOD	-1
15	growth	growth	I-NP	NN	I-protein	16	NMOD	0
16	factor	factor	I-NP	NN	I-protein	12	PMOD	-1
17	and	and	O	CC	O	21	NMOD	-1
18	new	new	B-NP	JJ	O	21	NMOD	-1
19	small	small	I-NP	JJ	O	21	NMOD	-1
20	vessel	vessel	I-NP	NN	O	21	NMOD	-1
21	formation	formation	I-NP	NN	O	9	OBJ	2	formation
22	at	at	B-PP	IN	O	9	VMOD	-1
23	the	the	B-NP	DT	O	24	NMOD	-1
24	sites	site	I-NP	NNS	O	22	PMOD	-1
25	of	of	B-PP	IN	O	24	NMOD	-1
26	native	native	B-NP	JJ	O	28	NMOD	-1
27	vessel	vessel	I-NP	NN	O	28	NMOD	-1
28	stenosis	stenosis	I-NP	NN	O	30	NMOD	-1
29	or	or	O	CC	O	30	NMOD	-1
30	occlusion	occlusion	B-NP	NN	O	25	PMOD	-1
31	(	(	O	(	O	36	DEP	-1
32	p	p	B-NP	NN	O	36	DEP	-1
33	less	less	B-ADJP	JJR	O	32	NMOD	-1
34	than	than	B-PP	IN	O	33	AMOD	-1
35	0.001	0.001	B-NP	CD	O	34	PMOD	-1
36	)	)	O	)	O	30	NMOD	-1
37	.	.	O	.	O	4	P	-1

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	Irreversible	Irreversible	B-NP	JJ	O	4	NMOD	-1
4	PHT	PHT	I-NP	NN	O	5	SUB	-1
5	is	be	B-VP	VBZ	O	1	NMOD	-1
6	strongly	strongly	I-VP	RB	O	5	VMOD	-1
7	associated	associate	I-VP	VBN	O	5	VC	0
8	with	with	B-PP	IN	O	7	VMOD	-1
9	impaired	impaired	B-NP	JJ	O	12	NMOD	18	impaired
10	endothelial	endothelial	I-NP	JJ	O	12	NMOD	-1
11	cell	cell	I-NP	NN	O	12	NMOD	-1
12	apoptosis	apoptosis	I-NP	NN	O	15	NMOD	5	apoptosis
13	and	and	O	CC	O	15	NMOD	-1
14	antiapoptotic	antiapoptotic	B-NP	JJ	O	15	NMOD	-1
15	signaling	signaling	I-NP	NN	O	8	PMOD	0
16	from	from	B-PP	IN	O	15	NMOD	-1
17	perivascular	perivascular	B-NP	JJ	B-cell_type	19	NMOD	-1
18	inflammatory	inflammatory	I-NP	JJ	I-cell_type	19	NMOD	-1
19	cells	cell	I-NP	NNS	I-cell_type	16	PMOD	-1
20	.	.	O	.	O	1	P	-1

1	These	These	B-NP	DT	O	2	NMOD	-1
2	changes	change	I-NP	NNS	O	3	SUB	0
3	are	be	B-VP	VBP	O	0	ROOT	-1
4	associated	associate	I-VP	VBN	O	3	VC	0
5	with	with	B-PP	IN	O	4	VMOD	-1
6	intimal	intimal	B-NP	JJ	O	7	NMOD	-1
7	proliferation	proliferation	I-NP	NN	O	10	NMOD	4	proliferation
8	and	and	O	CC	O	10	NMOD	-1
9	vessel	vessel	B-NP	NN	O	10	NMOD	-1
10	narrowing	narrowing	I-NP	NN	O	5	PMOD	-1
11	,	,	O	,	O	4	P	-1
12	and	and	O	CC	O	4	VMOD	-1
13	thereby	thereby	B-VP	RB	O	4	VMOD	-1
14	may	may	I-VP	MD	O	3	VMOD	-1
15	contribute	contribute	I-VP	VB	O	14	VC	0
16	to	to	B-PP	TO	O	15	VMOD	-1
17	clinical	clinical	B-NP	JJ	O	18	NMOD	-1
18	outcomes	outcome	I-NP	NNS	O	16	PMOD	-1
19	associated	associate	B-VP	VBN	O	18	NMOD	0
20	with	with	B-PP	IN	O	19	VMOD	-1
21	pulmonary	pulmonary	B-NP	JJ	O	22	NMOD	-1
22	hypertension	hypertension	I-NP	NN	O	20	PMOD	-1
23	.	.	O	.	O	3	P	-1

